Why Alacris

Why Alacris Theranostics ?

Exceptional scientific heritage and expertise

Human beings are unique and so are their diseases, often leading to a lack of response to the drugs they receive and in a significant number of cases, serious adverse drug reactions. In cancer, this situation is exacerbated by the fact that tumors are very heterogeneous. Tumor heterogeneity can exist between tumors of the same type but also within tumors, leading to different responses to therapy. The complex molecular profiles of tumors and their microenvironment are mostly unknown at the time of treatment, causing a large fraction of patients to remain refractory to treatment with even the most effective drugs we have available today.

The incorporation of precision medicine into the clinical setting is becoming increasingly feasible, but the scope of analysis is, in most cases, limited to the search for single gene mutations, or known gene fusions.

The company holds a strategic position in the field of personalized medicine, capitalizing on its long-standing expertise in NGS technologies and high-dimensional data analysis. In the field of molecular oncology, more is definitely more. We have developed leading-edge, comprehensive molecular tumor analysis solutions, which offer many advantages over panel sequencing while remaining economically competitive.

There is a strong rationale for conducting comprehensive tumor analysis. Frequent intra-tumor heterogeneity in common cancer types calls for a deeper characterization of bulk samples. Moreover, more than a quarter of all cancers are either rare cancers or cancers of unknown origin. Analysis at the individual level is required for personalized treatment.

Based on the decades-long experience of the main founders in the analysis of the human genome and within the field of systems medicine, Alacris Theranostics proposes innovative solutions in molecular oncology. Cutting-edge precision medicine, through an exceptionally deep analysis of every patient, is combined with advanced systems medicine to generate virtual tumor models and further personalize treatment recommendations.

Our team has been working in the NGS field since 2008, with experience in both sequencing and NGS data analysis as part of a number of national and international research and commercial projects.

 

Outstanding innovative technologies

We offer our expertise to provide a wide range of cutting-edge services in the areas of systems biology, bioinformatics and NGS for research and commercial projects. Alacris’ proprietary technologies – the integrative NGS data analysis pipelines NGSightTM and OncovarTM, and the predictive modeling system ModCellTM – are not only enabling a highly innovative approach to cancer precision medicine but are also impacting targeted drug development, reducing costs and time to approval. Alacris’ unique and outstanding technology has been recognized by multiple awards, including the prestigious German Innovation Award in 2015.